Genmab and Sanquin collaborate on hemophilia research

February 2004
PharmaWatch: Biotechnology;February 2004, Vol. 3 Issue 2, p11
Market Research Report
Reports that Genmab AS has entered into a research venture with the Sanquin Blood Supply Foundation to develop and improve hemophiliac treatment. Discovery of a method for preventing inhibitory antibodies from binding to factor VIII therapy; Utilization of antibodies to block the sites where the inhibitory antibodies bind; Comments from Genmab CEO Lisa N. Drakeman on the agreement made with Sanquin.


Related Articles

  • GENMAB/ROCHE ANNOUNCE ANTIBODY DEVELOPMENT COLLABORATION.  // Worldwide Biotech;Jun2001, Vol. 13 Issue 6, p7 

    Announces the broad collaboration of Genmab A/S with the Roche company for the creation and development of human antibody therapeutics.

  • Genmab announces cancer antibody data.  // European Pharmaceutical Executive;Jul/Aug2007, p15 

    The article reports that Genmab A/S in Denmark has released a preclinical data which shows that its fully human zalutumumab antibody, marketed as HuMax-EGFr, may have broad potential to treat cancers that over-express several types of epidermal growth factor receptor (EGFr). According to Genmab...

  • Genmab Celebrates Return Of HuMax-CD4 Rights.  // Bioworld Week;7/9/2007, Vol. 15 Issue 28, p2 

    The article reports on the selling of Merck Serono SA's HuMax-CD4 drug to Denmark-based Genmab A/S. According to Genmab, it is moving ahead with its latest acquisition of HuMax-CD4 compound in cutaneous T-cell lymphoma after regaining full rights to the drug from partner Merck. The biotechnology...

  • Roche chooses to develop Genmab antibodies.  // PharmaWatch: Biotechnology;May 2004, Vol. 3 Issue 5, p8 

    Focuses on the selection of two Genmab AS antibodies by Roche as candidates for clinical development. Terms of the agreement; Production of antibody product candidates; Effectivity of the development of antibodies.

  • Genmab Further Validates its DuoBodyâ„¢ Technology with Janssen Biotech Agreement. Cartwright, Heather // PharmaDeals Review;2012, Vol. 2012 Issue 7, p103 

    Genmab has made further progress with its DuoBodyâ„¢ technology platform by agreeing to collaborate with Johnson & Johnson's Janssen Biotech to create and develop bispecific antibodies against multiple disease targets. Janssen will fund all research and Genmab will receive US$3.5 M upfront...

  • GENMAB UNVEILS ANTIBODY DEVELOPMENT WITH LUNDBECH.  // Biotech Equipment Update;Nov2010, Vol. 18 Issue 11, p8 

    The article reports on the agreement of Copenhagen, Denmark-based Genmab A/S to develop human antibody therapeutics for central nervous system (CNS) disorders with H. Lundbeck A/S. As part of the deal, Lundbeck will gain access to Genmab's antibody development capabilities and to take select...

  • COMPANY SPOTLIGHT - Genmab A/S.  // PharmaWatch: Monthly Review;Jun2008, Vol. 7 Issue 7, p39 

    The article features Genmab A/S, a biotechnology company engaged in discovery and development of human antibodies for the treatment of life-threatening diseases. The company owns and licenses patents, patent applications and other proprietary rights relating to human antibody technology. It has...

  • COMPANY SPOTLIGHT - Genmab.  // PharmaWatch: Biotechnology;Dec2009, Vol. 8 Issue 12, p26 

    The article presents a corporate profile for biotechnology company Genmab A/S in Denmark. It states that the company's main strategy focuses more in the discovery and development of human antibodies for treating diseases in the areas of cancer, infectious disease, and inflammatory conditions. It...

  • Genmab Boosts Balance Sheet via Retooled GSK Collaboration.  // BioWorld Today;7/2/2010, Vol. 21 Issue 127, p4 

    The article reports on the restructuring of the agreement between Genmab A/S and GlaxoSmithKline plc. In 2006, Genmab licensed rights to then-Phase III-stage anti-CD20 antibody ofatumumab to GlaxoSmithKline (GSK). The 250 million U.S. dollar worth of manufacturing facility purchased by Genmab...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics